N4 Pharma PLC Result of AGM (6581K)
23 Abril 2020 - 5:01AM
UK Regulatory
TIDMN4P
RNS Number : 6581K
N4 Pharma PLC
23 April 2020
23 April 2020
N4 Pharma plc
("N4 Pharma", the "Company" or the "Group")
Result of Annual General Meeting
N4 Pharma Plc (AIM: N4P), the specialist pharmaceutical company
developing Nuvec(R), a novel delivery system for cancer treatments
and vaccines, announces that at its annual general meeting ("AGM"),
held earlier today, all resolutions were duly passed. The results
of the proxy voting for the AGM are set out below.
% of
Total % of Total % of issued
votes votes Votes votes Total Votes share Votes
Resolution For(1) cast(2) Against cast(2) Cast(3) capital Withheld(4)
To receive
the annual
report and
audited accounts
for the year
ended 31 December
1 2019 30,624,816 100.00 - 0.00 30,625,416 30.18 200
-------------------- ----------- --------- --------- --------- ------------ --------- -------------
To re-elect
Nigel Theobald
as a director
2 of the Company 30,620,596 100.00 200 0.00 30,621,396 30.18 4,200
-------------------- ----------- --------- --------- --------- ------------ --------- -------------
To re-elect
David Templeton
as a director
3 of the Company 30,620,596 100.00 200 0.00 30,621,396 30.18 4,200
-------------------- ----------- --------- --------- --------- ------------ --------- -------------
To re-appoint
Saffery Champness
LLP as auditor
to the company
and authorise
the directors
to determine
4 their remuneration 30,624,796 100.00 200 0.00 30,625,596 30.18 200
-------------------- ----------- --------- --------- --------- ------------ --------- -------------
To authorise
the directors
5 to allot shares 30,620,396 100.00 200 0.00 30,621,396 30.18 4,200
-------------------- ----------- --------- --------- --------- ------------ --------- -------------
To disapply
pre-emption
6 rights* 30,618,996 100.00 200 0.00 30,620,596 30.18 5,000
-------------------- ----------- --------- --------- --------- ------------ --------- -------------
To adopt new
Articles of
Association
7 of the Company* 30,620,396 100.00 200 0.00 30,625,396 30.18 200
-------------------- ----------- --------- --------- --------- ------------ --------- -------------
Notes:
* Proposed as special resolutions
1. Any proxy votes that were at the discretion of the Chairman
are included in the "Total Votes For" each resolution
2. Percentage of votes cast excludes Votes Withheld
3. Total Votes Cast do not include withheld votes
4. Votes Withheld are not votes in law and do not count in the
number of votes counted for or against a resolution
Enquiries:
N4 Pharma Plc
Nigel Theobald, CEO Via Scott PR
Allenby Capital Limited Tel: +44(0)203 328 5656
James Reeve/Asha Chotai
Scott PR Tel: +44(0)1477 539 539
Georgia Smith
About N4 Pharma
N4 Pharma is a specialist pharmaceutical company developing a
novel delivery system for cancer and vaccine treatments using its
unique silica nanoparticle delivery system called Nuvec(R).
N4 Pharma's business model is to partner with companies
developing novel antigens for cancer and vaccine treatments to use
Nuvec(R) as the delivery vehicle to get their antigen into cells to
express the protein needed for the required immunity. As these
products progress through pre clinical and clinical programs, N4
Pharma will seek to receive up front payments, milestone payments
and ultimately royalty payments once products reach the market.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
RAGGCGDSCUDDGGX
(END) Dow Jones Newswires
April 23, 2020 06:01 ET (10:01 GMT)
N4 Pharma (LSE:N4P)
Gráfica de Acción Histórica
De Mar 2024 a Abr 2024
N4 Pharma (LSE:N4P)
Gráfica de Acción Histórica
De Abr 2023 a Abr 2024
